| Primary information |
|---|
| ID | 1842 |
| ThPP ID | Th1230 |
| Therapeutic Peptide/Protein Name | Human Varicella-Zoster Immune Globulin |
| Sequence | NA view full sequnce in fasta |
| Functional Classification | IIIa |
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting Point (℃) | NA |
| Half Life | 26.2 days |
| Description | Human Varicella-Zoster Immune Globulin is a solvent/detergent-treated sterile liquid preparation of purified human immune globulin G (IgG) containing antibodies to varicella zoster virus (anti-VZV). |
| Indication/Disease | Indicated for reducing the severity of chicken pox (varicella zoster virus) infections in high risk individuals after exposure |
| Pharmacodynamics | Provides passive immunization for nonimmune individuals exposed to varicella zoster virus, thereby reducing the severity of varicella infections |
| Mechanism of Action | NA |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | Peak plasma time: 4.5 days, Peak plasma concentration: 136 mIU/mL |
| Volume of Distribution | NA |
| Clearance | 0.204 mL/day |
| Categories | Antibody |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | The passive transfer of antibodies with immune globulin administration may impair the efficacy of live attenuated virus vaccines such as measles, rubella, mumps and varicella |
| Target | varicella zoster virus |
| Information of corresponding available drug in the market |
|---|
| Brand Name | VARIZIG |
| Company | NA |
| Brand Discription | VARIZIG [Varicella Zoster Immune Globulin (Human)] is a solvent/detergent-treated sterile liquid preparation of purified human immune globulin G (IgG) containing antibodies to varicella zoster virus (anti-VZV). VZV is the causative agent of chickenpox. VARIZIG is prepared from plasma donated by healthy, screened donors with high titers of antibodies to VZV, which is purified by an anion-exchange column chromatography manufacturing method |
| Prescribed for | It is indicated for post-exposure prophylaxis of varicella in high risk individuals. |
| Chemical Name | NA |
| Formulation | It is available in a single-use vial of 125 IU. Each 125 IU vial of VARIZIG contains less than 156 milligrams of total protein, mostly human immune globulin G (IgG). VARIZIG contains no preservative |
| Physcial Appearance | lyophilized powder for solution |
| Route of Administration | Intramuscular |
| Recommended Dosage | Depending on patient size, divide the IM dose and administer in 2 or more injection sites; not to exceed 3 mL/injection site |
| Contraindication | Hypersensitivity to human immunoglobulins |
| Side Effects | The most common adverse drug reactions (reported by ≥ 1% of subjects) observed in clinical trials for all subjects and patients (n=601) are the following:injection site pain (3%),headache (2%),rash (including terms pruritus, rash, rash erythematous, rash vesicular and urticaria) (1%),fatigue (1%),chills (1%),nausea (1%) |
| Useful Link | http://www.rxlist.com/varizig-drug.htm , http://reference.medscape.com/drug/varizig-varicella-zoster-immune-globulin-human-343145#0 |
| PubMed ID | 6341478 |
| 3-D Structure | N.A. |